Top 10 most-read articles of the year 2025
Weight-loss drugs, diabetes drugs, and glucose-monitoring devices. These three topics interested JUVE Patent readers the most over the past twelve months. Once again, news from the life sciences industry dominates the list of the most-read articles on JUVE Patent. But the biggest IP spin-off of the past 20 years as well as a slow juicer case were also popular.
19 December 2025 by Mathieu Klos
The weight-loss injection Wegovy was the talk of the town this year. Since October, JUVE Patent has published three news items on the miracle drug. Our news that the European Patent Office upheld a semaglutide patent owned by Novo Nordisk made it to the top of JUVE Patent’s most-read articles — and by a wide margin.
Readers were also particularly interested in news relating to pharma, biotech and medical devices. As in the previous year, news on mobile phone cases and streaming patents did not rank as highly. The news that the EU Commission withdrew its proposal for a new SEP regulation under pressure from industry associations landed in tenth place.
A year of upheaval
However, 2025 was also characterised by many changes in the world of law firms. These are a reaction to the launch of the Unified Patent Court. Pentarc is probably the largest spin-off of an IP team in Europe in the last 20 years. Reader interest in our breaking news at the beginning of September was correspondingly high.
But the readers of JUVE Patent are apparently (hopefully) also health-conscious. The fifth most-read article was the news that kitchen appliance manufacturer Hurom has suffered a setback against competitors NUC and Warmcook at the UPC’s Paris local division. The dispute concerns a technology for slow juicers.
And, of course, readers were also highly interested in what was probably the most significant legal decision of the year in BSH vs Electrolux. In May, the CJEU reopened cross-border litigation in Europe again. The effects of the decision will keep the patent community busy for some years.
These are the top ten most-read articles by JUVE Patent readers in 2025:
1. Novo Nordisk and D Young defend crucial patent for tablet form of semaglutide
2. UK High Court revokes AstraZeneca’s SPC and patent for diabetes drug dapagliflozin
3. Taylor Wessing Munich loses large portion of its patent litigation partners
4 Abbott vs Sinocare: UPC hears PI cases over glucose-monitoring devices
5. Paris local division hands NUC victory in slow juicer battle with Hurom
6. UK appeals court upholds cancellation of AstraZeneca’s diabetes SPC and patent
7. Moderna and Freshfields triumph in Düsseldorf against BioNTech and Pfizer
8 CJEU reopens European cross-border litigation in BSH vs Electrolux ruling
9. Bayer and Regeneron secure PI against Formycon concerning Eylea
10. Mixed reaction from market as EU withdraws SEP regulation
